All In Biotech

Drug Trial Radar · NCT06732401

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

A Randomized Phase III Trial of Checkpoint Blockade in Lung CancEr Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Aug 7, 2025

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Sponsor type
NIH
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Conditions

  • Lung Non-Small Cell Carcinoma
  • Stage II Lung Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • CeralasertibDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scan

  • DurvalumabBiological

    Given IV

  • Echocardiography TestProcedure

    Undergo echocardiography

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival (DFS)Time frame: From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years

Locations

192 sites in 1 country. Site status is shown where the registry gives one.

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • Tower Cancer Research Foundation

    Beverly Hills, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Cedars-Sinai Cancer - Tarzana

    Tarzana, California

  • Torrance Memorial Physician Network - Cancer Care

    Torrance, California

  • Hartford Hospital

    Hartford, Connecticut

  • Midstate Medical Center

    Meriden, Connecticut

  • The Hospital of Central Connecticut

    New Britain, Connecticut

  • Beebe South Coastal Health Campus

    Millville, Delaware

  • Helen F Graham Cancer Center

    Newark, Delaware

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware

  • Beebe Health Campus

    Rehoboth Beach, Delaware

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia

  • Emory Decatur Hospital

    Decatur, Georgia

  • Emory Johns Creek Hospital

    Johns Creek, Georgia

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois

  • Illinois CancerCare-Canton

    Canton, Illinois

  • Illinois CancerCare-Carthage

    Carthage, Illinois

  • Northwestern University

    Chicago, Illinois

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois

  • Decatur Memorial Hospital

    Decatur, Illinois

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois

  • Illinois CancerCare-Dixon

    Dixon, Illinois

  • Crossroads Cancer Center

    Effingham, Illinois

  • Illinois CancerCare-Eureka

    Eureka, Illinois

  • Illinois CancerCare-Galesburg

    Galesburg, Illinois

  • Northwestern Medicine Cancer Center Delnor

    Geneva, Illinois

  • Northwestern Medicine Glenview Outpatient Center

    Glenview, Illinois

Showing 40 of 192 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.